Revenue and Profit - Revenue for the three months ended June 30, 2021, was $303,786, a significant decrease of $1,220,076 or approximately 80.1% compared to $1,523,862 for the same period in 2020 due to COVID-19 lockdowns in Malaysia [194]. - Gross profit for the three months ended June 30, 2021, was $268,163, with a gross margin of approximately 88.3%, compared to a gross profit of $1,052,308 and a margin of approximately 69.1% for the same period in 2020 [196]. - Revenue for the six months ended June 30, 2021, was $605,566, a decrease of $918,296 or approximately 60.3% compared to $1,523,862 for the same period in 2020, despite full revenue contribution from ASL [204]. - Gross profit for the six months ended June 30, 2021, was $492,352, with a gross margin of approximately 81.3%, compared to $1,052,308 and a margin of approximately 69.1% for the same period in 2020 [208]. - The company incurred a net loss of $642,225 for the three months ended June 30, 2021, compared to a net income of $87,240 for the same period in 2020, a decrease of $729,465 [203]. - Net loss increased to $975,875 for the six months ended June 30, 2021, from a net loss of $144,510 for the same period in 2020, reflecting an increase of $831,365 [217]. Expenses - Operating expenses for the three months ended June 30, 2021, were $655,188, a decrease of $152,862 or approximately 29.7% compared to $808,050 for the same period in 2020, primarily due to reduced professional fees after the acquisition of ASL [199]. - Selling expenses for the six months ended June 30, 2021, amounted to $216,952, an increase of $107,596 or approximately 98.4% compared to $109,356 for the same period in 2020 [209]. - Commission expenses for the six months ended June 30, 2021, were $181,213, a significant decrease of $201,285 or 52.6% compared to $382,498 for the same period in 2020 [210]. - General and administrative (G&A) expenses for the six months ended June 30, 2021, increased by approximately 7.5% to $724,008 from $673,778 for the same period in 2020 [211]. - Other expenses for the six months ended June 30, 2021, amounted to $214,277, a significant decrease of approximately 308.3% compared to $102,881 in other income for the same period in 2020 [215]. Cash Flow and Working Capital - Working capital as of June 30, 2021, was $3,747,830, down from $4,645,729 as of December 31, 2020, indicating a decrease of approximately 19.3% [223]. - Net cash used in operating activities for the six months ended June 30, 2021, was $134,748, a significant improvement compared to $780,664 for the same period in 2020 [227]. - Net cash used in investing activities for the six months ended June 30, 2021, was $1,220, compared to $1,280,991 provided by investing activities in the same period of 2020 [229]. - Net cash used in financing activities for the six months ended June 30, 2021, was $16,588, compared to $140,837 provided by financing activities in the same period of 2020 [231]. Provisions and Tax - The company recorded a provision for doubtful accounts of $121,686 for the three months ended June 30, 2021, a significant increase of 100.0% compared to $0 for the same period in 2020 [200]. - The company recorded a provision for income taxes of $10,091 for the six months ended June 30, 2021, compared to $134,067 for the same period in 2020 [216]. Business Operations and Market Expansion - The company anticipates expanding into Asian markets, focusing on Thailand, Indonesia, and Taiwan, primarily through e-commerce [222]. - The Company sells coupons to customers at a discounted price, with cash proceeds recognized as customer deposits until utilized, and forfeited sales value recognized as net revenues after six months [238]. - Revenues from Health and Wellness services are recognized when health screening test reports are completed and delivered, and upon completion of health camp programs [238]. Financial Instruments and Risks - Financial instruments in current assets and liabilities are reported at face value or cost, approximating fair value due to short realization periods [240]. - The Company does not expect recent accounting pronouncements to materially impact its financial condition or results of operations [240]. - The Company has not hedged foreign exchange risks, as most revenues are in U.S. dollars while expenses are in Malaysian Ringgit and Hong Kong Dollar [246]. - Credit risk is mitigated by ongoing credit evaluations and short collection terms, with no collateral generally required from customers [247].

[PART I FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20FINANCIAL%20INFORMATION) This section presents the unaudited condensed consolidated financial statements and related management discussion for the period ended March 31, 2021 [Unaudited Condensed Consolidated Financial Statements](index=4&type=section&id=ITEM%201.%20UNAUDITED%20CONDENSED%20CONSOLIDATED%20FINANCIAL%20STATEMENTS%3A) This section presents the unaudited condensed consolidated financial statements for Agape ATP Corporation, including balance sheets, statements of operations, equity changes, and cash flows, showing a net loss and asset decrease for the quarter ended March 31, 2021 [Unaudited Condensed Consolidated Balance Sheets](index=4&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to **$6.67 million** from **$7.21 million** as of March 31, 2021, primarily due to reduced current assets, alongside decreases in total liabilities and stockholders' equity Condensed Consolidated Balance Sheet Data (Unaudited) | Account | March 31, 2021 | December 31, 2020 | | :--- | :--- | :--- | | **Total Current Assets** | $5,122,995 | $5,684,271 | | **Total Assets** | **$6,666,027** | **$7,210,607** | | **Total Current Liabilities** | $916,983 | $1,038,542 | | **Total Liabilities** | **$1,113,127** | **$1,285,773** | | **Total Stockholders' Equity** | **$5,552,900** | **$5,924,834** | [Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) The company reported **$301,780** in revenue for Q1 2021, a significant increase from zero in Q1 2020, yet incurred a higher net loss of **$333,650** due to increased operating expenses Statement of Operations Highlights (Unaudited) | Metric | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | | :--- | :--- | :--- | | **Revenue** | $301,780 | $0 | | **Gross Profit** | $224,189 | $0 | | **Total Operating Expenses** | ($566,699) | ($159,516) | | **Loss from Operations** | ($342,510) | ($159,516) | | **Net Loss** | **($333,650)** | **($231,750)** | | **Net Loss Per Share (Basic and Diluted)** | $0.00 | $0.00 | [Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity](index=7&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders'%20Equity) Total stockholders' equity decreased to **$5.55 million** from **$5.92 million** by March 31, 2021, primarily due to the net loss and foreign currency translation adjustments - The accumulated deficit increased to **$1,068,093** as of March 31, 2021, from **$734,443** at December 31, 2020, reflecting the net loss for the quarter[16](index=16&type=chunk) [Unaudited Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities improved to **$129,297** in Q1 2021, with no investing activities and minimal financing cash usage, resulting in an overall decrease of **$163,042** in cash and cash equivalents Cash Flow Summary (Unaudited) | Cash Flow Activity | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | | :--- | :--- | :--- | | **Net cash used in operating activities** | ($129,297) | ($230,431) | | **Net cash provided by investing activities** | $0 | $70,173 | | **Net cash used in financing activities** | ($6,423) | $0 | | **Net change in cash and cash equivalents** | **($163,042)** | **($156,250)** | [Notes to Unaudited Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) These notes detail the company's Health and Wellness business in Malaysia, including the ASL acquisition, VIE consolidation, accounting policies, and significant risks such as those related to COVID-19 - The company is principally engaged in the Health and Wellness Industry, supplying products and programs like the 'ATP Zeta Health Program' and operates mainly in Malaysia[22](index=22&type=chunk)[26](index=26&type=chunk) - On May 8, 2020, the Company acquired approximately **99.99%** of Agape Superior Living Sdn Bhd (ASL) to secure an established network marketing sales channel in Malaysia[21](index=21&type=chunk)[27](index=27&type=chunk) - The company consolidates a Variable Interest Entity (VIE), Agape S.E.A. Sdn Bhd (SEA), which serves as a trading company for ASL's purchases[102](index=102&type=chunk) - The company faces significant risks from the COVID-19 pandemic, as substantially all revenues are concentrated in Malaysia, which has been subject to various movement control orders, potentially affecting demand, supply chains, and overall results[172](index=172&type=chunk)[173](index=173&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=37&type=section&id=ITEM%202.%20MANAGEMENT'S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS) Management discusses the Q1 2021 financial results, highlighting revenue generation from the ASL acquisition, an increased net loss due to higher operating expenses, and sufficient liquidity despite COVID-19 challenges, while also addressing critical accounting policies and internal control weaknesses [Results of Operation](index=39&type=section&id=Results%20of%20Operation) Q1 2021 revenue of **$301,780** from ASL operations led to a gross profit of **$224,189**, but a surge in operating expenses, particularly G&A, resulted in a wider net loss of **$333,650** Q1 2021 vs Q1 2020 Performance | Metric | Q1 2021 | Q1 2020 | | :--- | :--- | :--- | | Revenue | $301,780 | $0 | | Gross Profit | $224,189 | $0 | | G&A Expenses | $362,146 | $159,516 | | Net Loss | ($333,650) | ($231,750) | - The increase in G&A expenses by **$202,630** (**127%**) was predominantly due to increased salary and employee benefit expenses from the ASL acquisition[190](index=190&type=chunk) [Liquidity and Capital Resources](index=40&type=section&id=Liquidity%20and%20Capital%20Resources) Working capital decreased to **$4.2 million** by March 31, 2021, yet management deems resources sufficient for the next 12 months, despite ongoing COVID-19 impacts in Malaysia and plans for e-commerce expansion into other Asian markets - Working capital was **$4,206,012** as of March 31, 2021, and management believes cash resources are sufficient for the next **12** months[198](index=198&type=chunk) - The company's operations are significantly impacted by COVID-19 related movement control orders in Malaysia, its primary revenue source[194](index=194&type=chunk)[196](index=196&type=chunk) - Net cash used in operating activities improved to **$129,297** in Q1 2021 from **$230,431** in Q1 2020[201](index=201&type=chunk)[202](index=202&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=46&type=section&id=ITEM%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK) The company faces unhedged foreign exchange risk between the U.S. dollar, Malaysian Ringgit, and Hong Kong Dollar, while managing credit risk from accounts receivable through evaluation and short collection terms - The company faces foreign exchange risk between the U.S. dollar, Malaysian Ringgit, and Hong Kong Dollar, but does not currently hedge this risk[220](index=220&type=chunk) - Credit risk from accounts receivable is managed through credit evaluations and short collection terms, and the company does not generally require collateral[221](index=221&type=chunk) [Controls and Procedures](index=46&type=section&id=ITEM%204.%20CONTROLS%20AND%20PROCEDURES) Management identified material weaknesses in internal controls over financial reporting as of March 31, 2021, including insufficient U.S. GAAP expertise and inadequate segregation of duties, with remediation efforts underway including a new CFO appointment and plans for an internal audit function - Management concluded that internal controls over financial reporting were not effective as of March 31, 2021[225](index=225&type=chunk) - Identified material weaknesses include: (i) lack of sufficient U.S. GAAP accounting expertise, (ii) lack of an internal audit function, (iii) inadequate segregation of duties, (iv) poor system change management, (v) weak data security access controls, and (vi) lack of qualified personnel for U.S. tax provisions (Subpart F and GILTI)[227](index=227&type=chunk) - Remediation efforts include the appointment of a CFO on January 12, 2021, and plans to establish an internal audit function, engage consultants, and hire a U.S. tax professional[229](index=229&type=chunk)[230](index=230&type=chunk)[231](index=231&type=chunk) [PART II OTHER INFORMATION](index=49&type=section&id=PART%20II%20OTHER%20INFORMATION) This section provides additional information not covered in the financial statements, including legal proceedings, equity sales, and exhibits [Legal Proceedings](index=49&type=section&id=ITEM%201%20Legal%20PROCEEDINGS) The company reports no material, active, or pending legal proceedings against it - There are no known material, active, or pending legal proceedings against the company[233](index=233&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=49&type=section&id=ITEM%202%20UNREGISTERED%20SALES%20OF%20EQUITY%20SECURITIES%20AND%20USE%20OF%20PROCEEDS) There were no unregistered sales of equity securities during the reporting period - None[233](index=233&type=chunk) [Other Information](index=49&type=section&id=ITEM%205%20OTHER%20INFORMATION) The company reported no other information required to be disclosed in this item - None[233](index=233&type=chunk) [Exhibits](index=50&type=section&id=ITEM%206%20EXHIBITS) This section lists the exhibits filed with the Form 10-Q, including officer certifications (31.1, 32.1) and XBRL data files - Exhibits filed include Rule 13(a)-14(a)/15(d)-14(a) Certification, Section 1350 Certification, and various XBRL documents[234](index=234&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number 333-220144 AGAPE ATP CORPORATION (Exact name of registrant issuer as specified in its charter) | --- | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number 333-220144 AGAPE ATP CORPORATION (Exact name of registrant issuer as specified in its charter) | --- | --- | |-- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended March 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number 333-220144 AGAPE ATP CORPORATION (Exact name of registrant issuer as specified in its charter) Nevada 36-48 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [ ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended _______________________ or [X] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from July 1, 2019 to December 31, 2019 Commission File Number 333-220144 AGAPE ATP CORPORATION (Exact name of registrant issuer as specified in its charter) | --- | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended September 30, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number 333-220144 AGAPE ATP CORPORATION (Exact name of registrant issuer as specified in its charter) Nevada 3 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Quarterly Period Ended March 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number 333-220144 AGAPE ATP CORPORATION (Exact name of registrant issuer as specified in its charter) Nevada 36-48 ...